v
irus
gener
neglect
caus
communityacquir
pneumonia
cap
number
understand
reason
includ
investig
epidemiolog
studi
routin
sought
clinic
practic
diffi
cult
diagnos
primarili
method
use
purpos
cultur
immunofl
uoresc
viral
antigen
serolog
expens
often
unavail
result
becom
known
time
manner
addit
avail
antivir
agent
use
therapeut
rapidli
clinic
effect
come
expect
antibacteri
therapi
howev
viral
epidem
attract
attent
becam
clear
hantaviru
new
mexico
sever
acut
respiratori
syndrom
sar
associ
coronaviru
asia
novel
influenza
worldwid
latter
instanc
appreci
import
clinic
role
pathogen
could
lead
nonpneumon
lower
respiratori
tract
infect
tracheobronch
viral
pneumonia
often
acut
lung
injuri
secondari
bacteri
pneumonia
probabl
asymptomat
coloniza
tion
carriag
sever
infect
novel
patient
age
elderli
season
influenza
made
us
pay
attent
becam
familiar
nucleic
acid
amplifi
cation
test
naat
method
defi
nitiv
diagnosi
sought
new
strategi
therapi
compel
reason
establish
defi
nitiv
diagnosi
epidem
viral
infect
even
absenc
optim
therapi
identifi
infect
patient
could
effect
isol
also
identifi
noninfect
patient
could
remov
isol
clinic
present
lower
respiratori
tract
infect
virus
recogn
common
caus
cap
yet
littl
attent
paid
organ
clinic
practic
diagnost
therapeut
limit
discuss
although
infl
uenza
remain
predomin
viral
caus
cap
adult
american
thorac
diseas
societi
america
guidelin
cap
includ
commonli
recogn
virus
respiratori
syncyti
viru
rsv
adenoviru
parainfl
uenza
viru
well
less
common
virus
includ
human
metapneumoviru
herp
simplex
viru
varicellazost
viru
sarsassoci
coronaviru
measl
viru
studi
cap
spain
chile
use
immunofl
uoresc
antigen
detect
method
incid
cap
caus
viral
infect
immunecompet
individu
vari
chilean
studi
viral
pneumonia
particularli
common
elderli
patient
interestingli
chilean
studi
pure
viral
infect
present
patient
cap
commonli
found
patient
receiv
outpati
antimicrobi
impli
mani
patient
may
bacteri
coinfect
bacteri
compon
elimin
use
antibiot
hospit
incid
viral
cap
high
outpati
includ
naat
test
use
virus
also
probabl
play
pathogen
role
ventilatorassoci
pneumonia
sever
ill
icu
serv
primari
etiolog
pathogen
probabl
copathogen
bacteri
organ
potenti
role
viru
reactiv
set
acut
ill
occur
cytomegaloviru
herp
simplex
viru
bronchopneumon
diagnos
immunocompet
mechan
ventil
patient
show
clinic
deteriori
cytomegaloviru
cmv
report
mechan
ventil
immunocompet
patient
icu
patient
sever
ill
seem
like
patient
critic
ill
acquir
diseaserel
immun
suppress
predispos
cmv
reactiv
turn
potenti
infl
ammatori
infecti
process
although
remain
uncertain
antivir
therapi
provid
clinic
benefi
patient
exact
incid
virus
cap
still
uncertain
methodolog
limit
prior
studi
mention
recent
naat
techniqu
becom
wide
use
fi
nding
methodolog
may
differ
fi
nding
obtain
older
potenti
less
sensit
specifi
c
method
naat
abl
diagnos
infect
virus
detect
convent
method
metapneumoviru
rhinoviru
coronaviru
one
studi
use
techniqu
virus
detect
patient
cap
compar
convent
method
naat
techniqu
current
avail
simultan
detect
multipl
virus
respiratori
tract
sampl
rapid
fashion
give
result
hour
method
base
revers
transcriptas
polymeras
chain
reaction
pcr
aim
detect
viral
rna
use
amplifi
cation
viral
target
combin
viralspecifi
c
probe
label
fl
uoresc
beacon
detect
quantifi
amount
viral
materi
present
real
time
multipl
virus
detect
simultan
refer
multiplex
realtim
pcr
assay
previou
studi
viral
cap
examin
patient
pneumonia
compar
fi
nding
popul
frequenc
virus
patient
lower
respiratori
infect
frequenc
healthi
adult
carrier
acut
infect
addit
uncertain
respiratori
sampl
provid
highest
sensit
detect
viral
pathogen
issu
chest
see
page
lieberman
colleagu
use
naat
methodolog
provid
data
frequenc
ident
viral
caus
hospit
patient
lower
respiratori
tract
infect
compar
find
radiograph
confi
rmed
cap
fi
nding
ambulatori
control
popul
without
respiratori
tract
infect
hospit
popul
nonpneumon
lower
respiratori
tract
infect
nplrti
studi
patient
sampl
collect
three
method
evalu
multiplex
realtim
pcr
sampl
came
nasopharyng
swab
oropharyng
swab
nasopharyng
wash
separ
studi
author
demonstr
nasopharyng
wash
sensit
method
detect
presenc
viral
infect
frequenc
viral
cap
patient
compar
control
nplrti
common
viral
caus
cap
coronaviru
agent
usual
recov
unless
naat
test
done
coronaviru
occur
signifi
cantli
commonli
patient
cap
control
recoveri
rate
patient
nplrti
similar
patient
cap
rhinoviru
rsv
infl
uenza
viru
next
common
caus
viral
cap
order
interestingli
infl
uenza
viru
much
common
nplrti
cap
studi
presenc
viral
infect
correl
clinic
fi
nding
radiograph
presenc
pneumonia
patient
age
smoke
histori
patient
viral
cap
less
like
smoker
without
fi
nding
studi
uniqu
sever
way
popul
studi
naat
usual
clinic
avail
yield
like
increas
inclus
sampl
collect
three
differ
method
addit
frequenc
viral
cap
put
context
demonstr
virus
even
common
patient
nplrti
frequenc
posit
test
zero
control
impli
patient
carrier
viral
infect
colon
without
becom
ill
major
limit
studi
perform
two
winter
season
continu
period
also
presenc
viral
infect
correl
sever
ill
presenc
bacteri
copathogen
thu
know
mani
patient
cap
posit
viral
naat
result
could
manag
without
receiv
antibiot
therapi
addit
possibl
naat
test
sensit
posit
result
alway
mean
viru
caus
cap
viru
could
simpli
colon
patient
serv
predispos
factor
secondari
bacteri
pneumonia
thu
mani
question
remain
includ
role
virus
play
cap
pathogenesi
potenti
benefi
antivir
therapi
would
avail
futur
virus
common
primari
pathogen
antivir
therapi
might
valuabl
cap
manag
wwwchestpubsorg
instanc
antibiot
could
avoid
similarli
virus
copathogen
therapi
could
potenti
mitig
sever
ill
even
prevent
develop
bacteri
superinfect
howev
virus
simpli
colon
suggest
recoveri
control
popul
naat
method
use
unclear
antivir
therapi
would
benefi
colon
patient
develop
cap
data
studi
lieberman
colleagu
provoc
demonstr
naat
method
use
high
frequenc
viral
detect
patient
lower
respiratori
tract
infect
avail
new
diagnost
tool
naat
abl
ask
question
clinic
relev
impact
respiratori
virus
might
abl
combin
posit
test
respiratori
viru
measur
serum
biomark
procalcitonin
patient
radiograph
cap
defi
ne
individu
manag
without
antibiot
new
diagnost
tool
viral
respiratori
tract
infect
might
also
encourag
develop
new
antivir
therapi
could
effect
improv
patient
outcom
thu
current
avail
data
shown
virus
commonli
present
patient
cap
caus
harm
yet
clinic
practic
rare
tri
diagnos
presenc
may
chang
new
diagnost
tool
becom
wide
avail
especi
help
us
defi
ne
etiolog
role
pathogen
encourag
develop
new
effect
antivir
therapi
h
ereditari
hemorrhag
telangiectasia
hht
hereditari
diseas
character
widespread
develop
telangiectasia
arterioven
malform
avm
frequent
genotyp
due
mutat
eng
avm
commonli
seen
liver
lung
brain
incid
pulmonari
avm
pavm
vari
wide
depend
screen
techniqu
underli
genotyp
pavm
associ
signifi
cant
morbid
untreat
embol
therapi
highli
effect
accur
diagnosi
import
past
decad
transthorac
contrast
echocardiographi
ttce
agit
salin
contrast
